NASDAQ:APYX

Apyx Medical (APYX) Stock Price, News & Analysis

$1.45
-0.03 (-2.03%)
(As of 04/26/2024 08:52 PM ET)
Today's Range
$1.42
$1.53
50-Day Range
$1.25
$2.32
52-Week Range
$1.21
$7.97
Volume
58,300 shs
Average Volume
143,488 shs
Market Capitalization
$50.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.17

Apyx Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
325.3% Upside
$6.17 Price Target
Short Interest
Healthy
1.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
0.58mentions of Apyx Medical in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.74) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

111th out of 916 stocks

Surgical & Medical Instruments Industry

15th out of 91 stocks

APYX stock logo

About Apyx Medical Stock (NASDAQ:APYX)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

APYX Stock Price History

APYX Stock News Headlines

His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
Apyx Medical Corporation (APYX)
His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
Apyx Medical (APYX) Receives a Hold from JMP Securities
Q4 2023 Apyx Medical Corp Earnings Call
Apyx: Q4 Earnings Snapshot
APYX Apr 2024 5.000 put
Craig-Hallum Gives a Buy Rating to Codexis (CDXS)
See More Headlines
Receive APYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apyx Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/28/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:APYX
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.17
High Stock Price Target
$9.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+325.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,710,000.00
Pretax Margin
-40.65%

Debt

Sales & Book Value

Annual Sales
$52.35 million
Book Value
$0.78 per share

Miscellaneous

Free Float
30,106,000
Market Cap
$50.23 million
Optionable
Optionable
Beta
1.09
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

APYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Apyx Medical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APYX shares.
View APYX analyst ratings
or view top-rated stocks.

What is Apyx Medical's stock price target for 2024?

2 equities research analysts have issued 12-month price objectives for Apyx Medical's shares. Their APYX share price targets range from $4.50 to $9.00. On average, they anticipate the company's share price to reach $6.17 in the next twelve months. This suggests a possible upside of 325.3% from the stock's current price.
View analysts price targets for APYX
or view top-rated stocks among Wall Street analysts.

How have APYX shares performed in 2024?

Apyx Medical's stock was trading at $2.62 at the beginning of the year. Since then, APYX shares have decreased by 44.7% and is now trading at $1.45.
View the best growth stocks for 2024 here
.

Are investors shorting Apyx Medical?

Apyx Medical saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 371,100 shares, a decline of 47.5% from the March 31st total of 706,700 shares. Based on an average daily trading volume, of 154,700 shares, the short-interest ratio is presently 2.4 days. Approximately 1.3% of the shares of the company are short sold.
View Apyx Medical's Short Interest
.

When is Apyx Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our APYX earnings forecast
.

How can I listen to Apyx Medical's earnings call?

Apyx Medical will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745889".

How were Apyx Medical's earnings last quarter?

Apyx Medical Co. (NASDAQ:APYX) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $14.66 million for the quarter, compared to analysts' expectations of $14.40 million. Apyx Medical had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 35.75%.

What guidance has Apyx Medical issued on next quarter's earnings?

Apyx Medical issued an update on its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $49.7 million-$52.9 million, compared to the consensus revenue estimate of $59.8 million.

What other stocks do shareholders of Apyx Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), ONEOK (OKE), Occidental Petroleum (OXY), Procter & Gamble (PG), STORE Capital (STOR), Wells Fargo & Company (WFC), Boeing (BA), Bank of America (BAC) and Delta Air Lines (DAL).

Who are Apyx Medical's major shareholders?

Apyx Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Silverberg Bernstein Capital Management LLC (1.79%). Insiders that own company stock include Charles D Goodwin II, Matthew C Hill and Todd Hornsby.
View institutional ownership trends
.

How do I buy shares of Apyx Medical?

Shares of APYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APYX) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners